Drug Profile
Sodium phenylbutyrate - Acer Therapeutics
Alternative Names: ACER 001; OLPRUVALatest Information Update: 23 Nov 2023
Price :
$50
*
At a glance
- Originator Baylor College of Medicine
- Developer Acer Therapeutics; RELIEF THERAPEUTICS Holding
- Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
- Mechanism of Action Ammonia scavengers; Histone deacetylase inhibitors; Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Inborn urea cycle disorders
- Phase I Maple syrup urine disease
Most Recent Events
- 20 Nov 2023 Acer Therapeutics has been acquired by Zevra Therapeutics
- 14 Aug 2023 Acer plans to expand OLPRUVATM's label, exploring different dosage strengths for lighter patients and considering administration via a G-tube in 1H of 2024
- 27 Mar 2023 Acer Therapeutics plans to launch ACER 001 for Inborn urea cycle disorders in USA, in early July 2023